Edition:
United States

Active Biotech AB (ACTI.ST)

ACTI.ST on Stockholm Stock Exchange

2.77SEK
23 Feb 2018
Change (% chg)

-0.09kr (-2.98%)
Prev Close
2.85kr
Open
2.85kr
Day's High
2.92kr
Day's Low
2.72kr
Volume
224,240
Avg. Vol
592,219
52-wk High
21.90kr
52-wk Low
1.60kr

Latest Key Developments (Source: Significant Developments)

Active Biotech carries out 48 mln SEK rights issue
Thursday, 15 Feb 2018 02:31am EST 

Feb 15 (Reuters) - Active Biotech Ab ::ACTIVE BIOTECH CARRIES OUT RIGHTS ISSUE.ACTIVE BIOTECH AB SAYS HAS RESOLVED TO MAKE A RIGHTS ISSUE OF APPROXIMATELY SEK 48 MILLION BEFORE ISSUE COSTS‍​.ACTIVE BIOTECH AB SAYS SHAREHOLDERS SHALL BE ENTITLED TO SUBSCRIBE FOR THE NEW SHARES WITH PRE-EMPTIVE RIGHTS, WHEREBY TWO EXISTING SHARES SHALL ENTITLE TO SUBSCRIPTION FOR ONE NEW SHARE.ACTIVE BIOTECH AB SAYS SUBSCRIPTION PRICE SHALL BE SEK 1 PER SHARE.ACTIVE BIOTECH AB SAYS COMPANY HAS ENTERED SUBSCRIPTION COMMITMENTS AND ISSUE GUARANTEE OF APPROXIMATELY SEK 30 MILLION, CORRESPONDING TO APPROXIMATELY 61 PERCENT OF THE RIGHTS ISSUE.ACTIVE BIOTECH SAYS RIGHTS ISSUE AIMS AT PROVIDING THE FINANCIAL STABILITY REQUIRED TO AWAIT THE OUTCOME OF ONGOING CLINICAL STUDIES AND TO CONDUCT NEGOTIATIONS WITH PARTNERS REGARDING OTHER DEVELOPMENT PROJECTS.  Full Article

Active Biotech AB Q4 Net Sales Down At SEK ‍5.4​ Million
Thursday, 15 Feb 2018 02:30am EST 

Feb 15 (Reuters) - ACTIVE BIOTECH AB ::Q4 NET SALES SEK ‍5.4​ MILLION VERSUS SEK 7.1 MILLION YEAR AGO.Q4 OPERATING LOSS SEK ‍58.4​ MILLION VERSUS LOSS SEK 13.5 MILLION YEAR AGO.  Full Article

Active Biotech ‍provides updated information about company's financial situation​
Thursday, 7 Dec 2017 01:00pm EST 

Dec 7 (Reuters) - Active Biotech Ab ::‍PROVIDES UPDATED INFORMATION ABOUT COMPANY'S FINANCIAL SITUATION​.‍BOARD HAS DECIDED TO SELL COMPANY'S PROPERTY IN LUND AS A POSSIBLE WAY OF GENERATING ADDITIONAL LIQUIDITY FOR COMPANY​.‍SALES PROCESS INITIATED BY BOARD REGARDING COMPANY'S PROPERTY IN LUND IS ONGOING BUT HAS NOT YET LED TO COMPLETION​.‍CURRENTLY HAS LIQUIDITY DEEMED NECESSARY TO FINANCE OPERATIONS UNTIL END OF Q2 OF 2018​.‍LOAN DEBT AMOUNTED TO SEK 210.8 MILLION ON SEPTEMBER 30, 2017​.ACTIVE BIOTECH - UNLESS A SALE OF PROPERTY OR ANOTHER SOLUTION IS ACHIEVED, CO WILL LACK FUNDING TO ENSURE BUSINESS COMING TWELVE-MONTH PERIOD​.ACTIVE BIOTECH - ‍ARPEGGIO STUDY RESULTS HAVE A DECISIVE NEGATIVE IMPACT ON CONTINUED DEVELOPMENT OF LAQUINIMOD IN PPMS.  Full Article

Active Biotech Announce Results In Arpeggio Phase II Trial With Laquinimod In Primary Progressive MS
Friday, 1 Dec 2017 07:00am EST 

Dec 1 (Reuters) - Active Biotech AB ::ACTIVE BIOTECH ANNOUNCE RESULTS IN ARPEGGIO PHASE II TRIAL WITH LAQUINIMOD IN PRIMARY PROGRESSIVE MS.  Full Article

Active Biotech Q2 operating loss 23.1 mln SEK
Thursday, 10 Aug 2017 02:30am EDT 

Aug 10 (Reuters) - Active Biotech Ab :Active biotech ab q2 operating loss 23.1 million sek.Active biotech ab q2 sales 5.1 million sek.  Full Article

Active Biotech appoints Helen Tuvesson as new CEO
Monday, 19 Jun 2017 09:30am EDT 

June 19 (Reuters) - Active Biotech Ab :the Board has appointed the company's current CSO Helén Tuvesson as new CEO of Active Biotech AB.Tuvesson will take up the position on July 1.Tomas Leanderson, CEO since 2008, will be at the company's disposal during a transitional period.  Full Article

Active Biotech Q4 operating loss narrows to SEK 13.5 mln
Thursday, 16 Feb 2017 02:30am EST 

Active Biotech Ab : Q4 net sales SEK 7.1 million versus SEK 5.0 million year ago . Q4 operating loss SEK 13.5 million versus SEK 28.2 million year ago .Says operations are progressing according to plan pending the Phase 3 results for laquinimod in the first half of 2017.  Full Article

Active Biotech to raise SEK 55 mln via rights issue
Monday, 14 Nov 2016 01:28am EST 

Active Biotech Ab : Active biotech carries out rights issue of approximately 55 million Swedish crowns ($6.03 million) . Says subscription price amounts to 8 crowns per share . Says shareholders of the company have pre-emptive rights to subscribe for the new shares, whereby 13 existing shares entitle to subscription for one new share. Subscription for shares in the rights issue can only be made with pre-emptive rights . Subscription shall be made during the period 23 November - 7 December 2016 . Says rights issue is at no cost guaranteed in its entirety by Active Biotech's largest shareholder MGA Holding AB . The rights issue that now is conducted aims at providing Active Biotech with the financial stability required to await the outcome of the ongoing phase 3 study of laquinimod for the treatment of RRMS and the phase 2 study for the treatment of PPMS . If the outcome of these studies is positive, the Company expects that a positive operating result can be achieved from and including the financial year 2018 .Says proceeds from the rights issue, approximately SEK 55 million at full subscription, are intended to be used mainly for general working capital requirements.  Full Article

Active Biotech Q3 loss narrows
Monday, 14 Nov 2016 01:20am EST 

Active Biotech Ab : Active biotech AB interim report January - September 2016 . Q3 net sales SEK 4.1 million (5.2 mln) . Q3 operating loss SEK 11.1 million (loss of 22.2 mln) .Cash and cash equivalents at the end of the period SEK 39.9 million.  Full Article

Active Biotech AB says no dividend would be paid
Friday, 27 May 2016 02:33am EDT 

Active Biotech Ab : Annual general meeting of active biotech ab . In accordance with board of directors' proposal, it was resolved that no dividend would be paid .Board members and managing director were discharged from liability with respect to their management of company for 2015.  Full Article